[go: up one dir, main page]

MX2016009056A - Composiciones y metodos para tratamiento de crecimiento celular anormal. - Google Patents

Composiciones y metodos para tratamiento de crecimiento celular anormal.

Info

Publication number
MX2016009056A
MX2016009056A MX2016009056A MX2016009056A MX2016009056A MX 2016009056 A MX2016009056 A MX 2016009056A MX 2016009056 A MX2016009056 A MX 2016009056A MX 2016009056 A MX2016009056 A MX 2016009056A MX 2016009056 A MX2016009056 A MX 2016009056A
Authority
MX
Mexico
Prior art keywords
treatment
methods
cell growth
abnormal cell
compositions
Prior art date
Application number
MX2016009056A
Other languages
English (en)
Other versions
MX384259B (es
Inventor
Padval Mahesh
Okwabi NKANSAH Paul
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of MX2016009056A publication Critical patent/MX2016009056A/es
Publication of MX384259B publication Critical patent/MX384259B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

Esta invención se refiere a formas de dosificación oral y métodos que son útiles en el tratamiento de crecimiento celular anormal, tal como cáncer, en mamíferos, especialmente humanos.
MX2016009056A 2014-01-09 2015-01-09 Composiciones y metodos para tratamiento de crecimiento celular anormal. MX384259B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461925467P 2014-01-09 2014-01-09
PCT/US2015/010810 WO2015106096A1 (en) 2014-01-09 2015-01-09 Compositions and methods for treatment of abnormal cell growth

Publications (2)

Publication Number Publication Date
MX2016009056A true MX2016009056A (es) 2017-01-23
MX384259B MX384259B (es) 2025-03-14

Family

ID=52434976

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009056A MX384259B (es) 2014-01-09 2015-01-09 Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2021008225A MX2021008225A (es) 2014-01-09 2016-07-08 Composiciones y metodos para tratamiento de crecimiento celular anormal.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021008225A MX2021008225A (es) 2014-01-09 2016-07-08 Composiciones y metodos para tratamiento de crecimiento celular anormal.

Country Status (15)

Country Link
US (3) US20150190346A1 (es)
EP (2) EP3900726A1 (es)
JP (5) JP6647204B2 (es)
KR (3) KR102444494B1 (es)
CN (3) CN106102744A (es)
AU (4) AU2015204597B2 (es)
BR (1) BR112016016021B1 (es)
CA (1) CA2936283C (es)
DK (1) DK3091981T3 (es)
ES (1) ES2870562T3 (es)
IL (2) IL246667B (es)
MX (2) MX384259B (es)
NZ (2) NZ760233A (es)
SG (2) SG11201605588YA (es)
WO (1) WO2015106096A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115844894B (zh) * 2018-05-15 2024-08-06 江苏豪森药业集团有限公司 包含第三代小分子egfr抑制剂的药物组合物及其制备方法
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
BR112022017578A2 (pt) * 2020-03-27 2022-10-18 Pfizer Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo
DK3965742T3 (da) * 2020-04-24 2023-07-31 Dr Falk Pharma Gmbh Systemisk formulering af et pyridinon-derivat til TG2-relaterede sygdomme
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024037498A1 (zh) * 2022-08-15 2024-02-22 海创药业股份有限公司 一种治疗卵巢癌的联合用药物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) * 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
WO2005011634A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
NZ580372A (en) * 2007-04-18 2012-01-12 Pfizer Prod Inc Pyrimidine and triazine derivatives including a sulfonamide group for the treatment of abnormal cell growth such as cancer
RS61408B1 (sr) * 2008-08-13 2021-03-31 Vertex Pharma Farmaceutska kompozicija i njeno ordiniranje
WO2011112922A2 (en) * 2010-03-11 2011-09-15 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
JP2013536231A (ja) * 2010-08-23 2013-09-19 バーテックス ファーマシューティカルズ インコーポレイテッド （ｒ）−１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）−ｎ−（１−（２，３−ジヒドロキシプロピル）−６−フルオロ−２−（１−ヒドロキシ−２−メチルプロパン−２−イル）−１ｈ−インドール−５−イル）シクロプロパンカルボキサミドを含む医薬組成物およびその投与
AU2012225459A1 (en) * 2011-03-08 2013-10-10 Zalicus Pharmaceuticals Ltd. Solid dispersion formulations and methods of use thereof
EP2572731A1 (en) * 2011-09-26 2013-03-27 Abbott GmbH & Co. KG Formulations based on solid dispersions
DK3698790T3 (da) * 2014-02-07 2023-06-19 Verastem Inc Fremgangsmåder til behandling af abnorm cellevækst
US10532056B2 (en) * 2015-06-29 2020-01-14 Verastem, Inc. Therapeutic compositions, combinations, and methods of use

Also Published As

Publication number Publication date
NZ721934A (en) 2022-04-29
US20200038331A1 (en) 2020-02-06
US20150190346A1 (en) 2015-07-09
CN106102744A (zh) 2016-11-09
AU2020210153B2 (en) 2022-07-21
BR112016016021A8 (pt) 2018-04-17
IL292054A (en) 2022-06-01
SG10201805890QA (en) 2018-08-30
JP6647204B2 (ja) 2020-02-14
EP3091981B1 (en) 2021-03-10
JP2023065568A (ja) 2023-05-12
KR20160104725A (ko) 2016-09-05
CN119868364A (zh) 2025-04-25
CN115708827A (zh) 2023-02-24
KR20220130251A (ko) 2022-09-26
NZ760233A (en) 2022-04-29
SG11201605588YA (en) 2016-08-30
IL246667B (en) 2022-05-01
DK3091981T3 (da) 2021-05-31
JP2020007355A (ja) 2020-01-16
WO2015106096A1 (en) 2015-07-16
ES2870562T3 (es) 2021-10-27
EP3091981A1 (en) 2016-11-16
BR112016016021B1 (pt) 2023-01-10
AU2022256144A1 (en) 2022-11-24
KR20240159639A (ko) 2024-11-05
KR102444494B1 (ko) 2022-09-20
CA2936283A1 (en) 2015-07-16
AU2015204597B2 (en) 2020-04-30
AU2020210153A1 (en) 2020-08-13
AU2025204843A1 (en) 2025-07-17
AU2022256144B2 (en) 2025-04-03
MX2021008225A (es) 2021-08-11
BR112016016021A2 (pt) 2017-09-19
EP3900726A1 (en) 2021-10-27
IL246667A0 (en) 2016-08-31
US20230104303A1 (en) 2023-04-06
MX384259B (es) 2025-03-14
JP2017502062A (ja) 2017-01-19
JP2025084892A (ja) 2025-06-03
CA2936283C (en) 2023-02-28
JP2022001587A (ja) 2022-01-06
AU2015204597A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
ZA201800572B (en) Therapeutic compositions, combinations, and methods of use
MX2023010042A (es) Polinucleotidos moduladores.
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
GB2541571A (en) Pharmaceutical compositions
MX378145B (es) Formulaciones farmacéuticas tópicas que comprenden crisaborol para tratar afecciones inflamatorias
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
TW201613966A (en) SynTac polypeptides and uses thereof
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2017001103A (es) Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
PH12017501864A1 (en) Compositions and methods for treating autism